Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta employs its two proprietary platforms, Affimer and pre|CISION, to create novel diagnostic and therapeutic products. The COVID-19 pandemic thrust its ability to develop an Affimer-based LFT (lateral flow test) diagnostic into the spotlight, even though we believe greater long-term value lies within Therapeutics applications. While the COVID-19 opportunity didn’t pan out as many investors expected, it did showcase Avacta’s diagnostics capabilities and Affimers’ potential. Lead therapeutic asset AVA6000 is progressing through Phase I and should confirm the clinical utility of pre|CISION. A wider portfolio of products is being readied to exploit the platform’s tumour specific activation, which should result in greater potency and less toxicity. News flow over the next 18-24 months provides multiple value-inflection points. Our valuation is £557m, equivalent to 219p/share, from £710m, 280p/share previously.

Market information

SymbolPrimary exchanges


FY21 results: a year of frustrations and opportunities
Update | 06 Apr 2022
AffiDX LFT sales paused to improve Omicron detection
Lighthouse | 10 Jan 2022
Consumer testing CE mark received for AffiDX LFT
Lighthouse | 22 Dec 2021

Recent News

AffyXell JV milestone and increased equity stake
13 Apr 2022
AVA6000 poster presented at AACR
12 Apr 2022
AffyXell JV partners with Biocytogen and KNTSC
08 Apr 2022
Preliminary FY21 results
06 Apr 2022